{"id":29950,"date":"2025-03-19T15:54:29","date_gmt":"2025-03-19T07:54:29","guid":{"rendered":"https:\/\/flcube.com\/?p=29950"},"modified":"2025-03-19T15:54:32","modified_gmt":"2025-03-19T07:54:32","slug":"everest-medicines-initiates-jiashan-plant-for-etrasimod-tablet-production","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=29950","title":{"rendered":"Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production"},"content":{"rendered":"\n

China-based Everest Medicines (HKG: 1952<\/a>) announced the start of construction for a manufacturing plant in Jiashan, Zhejiang province, dedicated to producing its S1P receptor modulator etrasimod (formerly known as velsipity). The project, valued at RMB70 million (USD9.7 million), is expected to produce up to 50 million tablets of etrasimod upon completion, with supply covering mainland China, Hong Kong, Macao, Taiwan, South Korea, and Singapore.<\/p>\n\n\n\n

Production and Market Coverage<\/strong>
The new facility underscores Everest Medicines’ commitment to expanding its production capabilities to meet growing demand. The drug, registered in multiple regions including the United States, European Union, Canada, and others, was licensed from Arena Pharmaceuticals (now a Pfizer subsidiary) in 2017. This agreement granted Everest exclusive rights in Greater China and South Korea.<\/p>\n\n\n\n

Regulatory Milestones<\/strong>
A market filing for etrasimod as a treatment for moderate to severe active ulcerative colitis (UC) was accepted by China’s National Medical Products Administration (NMPA) in December 2024. Additionally, the drug gained access to 45 medical institutions in the Greater Bay Area through the “Hong Kong-Macau Drug and Device Access” policy, enhancing patient access across the region.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in…<\/p>\n","protected":false},"author":1,"featured_media":29951,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[126,1164,309],"class_list":["post-29950","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-everest-medicines","tag-hkg-1952","tag-pfizer"],"yoast_head":"\nEverest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in Jiashan, Zhejiang province, dedicated to producing its S1P receptor modulator etrasimod (formerly known as velsipity). The project, valued at RMB70 million (USD9.7 million), is expected to produce up to 50 million tablets of etrasimod upon completion, with supply covering mainland China, Hong Kong, Macao, Taiwan, South Korea, and Singapore.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=29950\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production\" \/>\n<meta property=\"og:description\" content=\"China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in Jiashan, Zhejiang province, dedicated to producing its S1P receptor modulator etrasimod (formerly known as velsipity). The project, valued at RMB70 million (USD9.7 million), is expected to produce up to 50 million tablets of etrasimod upon completion, with supply covering mainland China, Hong Kong, Macao, Taiwan, South Korea, and Singapore.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=29950\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-19T07:54:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-19T07:54:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1910-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"585\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29950#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29950\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production\",\"datePublished\":\"2025-03-19T07:54:29+00:00\",\"dateModified\":\"2025-03-19T07:54:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29950\"},\"wordCount\":191,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29950#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1910-png.avif\",\"keywords\":[\"Everest Medicines\",\"HKG: 1952\",\"Pfizer\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=29950#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29950\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=29950\",\"name\":\"Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29950#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29950#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1910-png.avif\",\"datePublished\":\"2025-03-19T07:54:29+00:00\",\"dateModified\":\"2025-03-19T07:54:32+00:00\",\"description\":\"China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in Jiashan, Zhejiang province, dedicated to producing its S1P receptor modulator etrasimod (formerly known as velsipity). The project, valued at RMB70 million (USD9.7 million), is expected to produce up to 50 million tablets of etrasimod upon completion, with supply covering mainland China, Hong Kong, Macao, Taiwan, South Korea, and Singapore.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29950#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=29950\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29950#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1910-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1910-png.avif\",\"width\":1080,\"height\":585,\"caption\":\"Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29950#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production - Insight, China's Pharmaceutical Industry","description":"China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in Jiashan, Zhejiang province, dedicated to producing its S1P receptor modulator etrasimod (formerly known as velsipity). The project, valued at RMB70 million (USD9.7 million), is expected to produce up to 50 million tablets of etrasimod upon completion, with supply covering mainland China, Hong Kong, Macao, Taiwan, South Korea, and Singapore.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=29950","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production","og_description":"China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in Jiashan, Zhejiang province, dedicated to producing its S1P receptor modulator etrasimod (formerly known as velsipity). The project, valued at RMB70 million (USD9.7 million), is expected to produce up to 50 million tablets of etrasimod upon completion, with supply covering mainland China, Hong Kong, Macao, Taiwan, South Korea, and Singapore.","og_url":"https:\/\/flcube.com\/?p=29950","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-19T07:54:29+00:00","article_modified_time":"2025-03-19T07:54:32+00:00","og_image":[{"width":1080,"height":585,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1910-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=29950#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=29950"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production","datePublished":"2025-03-19T07:54:29+00:00","dateModified":"2025-03-19T07:54:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=29950"},"wordCount":191,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=29950#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1910-png.avif","keywords":["Everest Medicines","HKG: 1952","Pfizer"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=29950#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=29950","url":"https:\/\/flcube.com\/?p=29950","name":"Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=29950#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=29950#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1910-png.avif","datePublished":"2025-03-19T07:54:29+00:00","dateModified":"2025-03-19T07:54:32+00:00","description":"China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in Jiashan, Zhejiang province, dedicated to producing its S1P receptor modulator etrasimod (formerly known as velsipity). The project, valued at RMB70 million (USD9.7 million), is expected to produce up to 50 million tablets of etrasimod upon completion, with supply covering mainland China, Hong Kong, Macao, Taiwan, South Korea, and Singapore.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=29950#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=29950"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=29950#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1910-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1910-png.avif","width":1080,"height":585,"caption":"Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=29950#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1910-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29950","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29950"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29950\/revisions"}],"predecessor-version":[{"id":29952,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29950\/revisions\/29952"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/29951"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29950"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29950"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29950"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}